M Ferrari1, C Comi2, F Marino3, L Magistrelli2, F De Marchi2, R Cantello2, G Riboldazzi4, G Bono4, M Cosentino3. 1. Center of Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n. 9, 21100, Varese, Italy. marco.ferrari@uninsubria.it. 2. Movement Disorders Centre, Neurology Unit, Department of Translational Medicine, University of Piemonte Orientale, Novara, Italy. 3. Center of Research in Medical Pharmacology, University of Insubria, Via Ottorino Rossi n. 9, 21100, Varese, Italy. 4. Departments of Biotechnology and Life Science, University of Insubria, Varese, Italy.
Abstract
BACKGROUND: Visual hallucinations (VHs) are frequent non-motor complication of Parkinson's disease (PD), associated to a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and psychosis in Alzheimer's disease, addictions, schizophrenia, and bipolar disorder. However, there are only a few studies on DR variants and VHs in PD, which did not provide conclusive results. OBJECTIVES: The present study aimed to determine whether genetic differences of DR are associated with visual hallucinations (VHs) in a cohort of Parkinson's disease (PD) patients. METHODS: A case-control study of 84 PD subjects, 42 with and 42 without VHs,that were matched for age, gender, disease duration, and dopaminergic medication was conducted. Polymerase chain reaction for SNPs in both D1-like (DRD1A-48G [rs4532] and C62T [rs686], DRD5T798C [rs6283]) and D2-like DR (DRD2G2137A [rs1800497] and C957T [rs6277], DRD3G25A [rs6280] and G712C [rs1800828], DRD4C616G [rs747302] and nR VNTR 48bp) analyzed genomic DNA. RESULTS: Patients carrying allele T at DRD1C62T had an increased risk of VHs, expressed as OR (95 % CI, p value), of 10.7 (2.9-40, p = 0.0001). Moreover, patients with DRD1-48 GG and 62TT genotype displayed shorter time to VHs, whereas a longer time to VHs was found in subjects carrying the DRD4 CG alleles. CONCLUSIONS: PD patients with VHs display higher frequency of DR SNPs associated with increased D1-like activity and decreased D2-like activity. Our data are in line with associations reported in other neurodegenerative and psychiatric conditions. Results likely provide valuable information for personalizing pharmacological therapy in PD patients.
BACKGROUND:Visual hallucinations (VHs) are frequent non-motor complication of Parkinson's disease (PD), associated to a negative prognosis. Previous studies showed an association between dopamine receptor (DR) gene (DR) variants and psychosis in Alzheimer's disease, addictions, schizophrenia, and bipolar disorder. However, there are only a few studies on DR variants and VHs in PD, which did not provide conclusive results. OBJECTIVES: The present study aimed to determine whether genetic differences of DR are associated with visual hallucinations (VHs) in a cohort of Parkinson's disease (PD) patients. METHODS: A case-control study of 84 PD subjects, 42 with and 42 without VHs,that were matched for age, gender, disease duration, and dopaminergic medication was conducted. Polymerase chain reaction for SNPs in both D1-like (DRD1A-48G [rs4532] and C62T [rs686], DRD5T798C [rs6283]) and D2-like DR (DRD2G2137A [rs1800497] and C957T [rs6277], DRD3G25A [rs6280] and G712C [rs1800828], DRD4C616G [rs747302] and nR VNTR 48bp) analyzed genomic DNA. RESULTS:Patients carrying allele T at DRD1C62T had an increased risk of VHs, expressed as OR (95 % CI, p value), of 10.7 (2.9-40, p = 0.0001). Moreover, patients with DRD1-48 GG and 62TT genotype displayed shorter time to VHs, whereas a longer time to VHs was found in subjects carrying the DRD4 CG alleles. CONCLUSIONS:PDpatients with VHs display higher frequency of DR SNPs associated with increased D1-like activity and decreased D2-like activity. Our data are in line with associations reported in other neurodegenerative and psychiatric conditions. Results likely provide valuable information for personalizing pharmacological therapy in PDpatients.
Entities:
Keywords:
Association studies in genetics; Hallucinations; Parkinson’s disease
Authors: Jennifer Simpson; Glenn Vetuz; Mathew Wilson; Keeley J Brookes; Lindsey Kent Journal: Am J Med Genet B Neuropsychiatr Genet Date: 2010-09 Impact factor: 3.568
Authors: A H Evans; A D Lawrence; J Potts; L MacGregor; R Katzenschlager; K Shaw; J Zijlmans; A J Lees Journal: J Neurol Neurosurg Psychiatry Date: 2006-03 Impact factor: 10.154
Authors: Caroline H Williams-Gray; Sarah L Mason; Jonathan R Evans; Thomas Foltynie; Carol Brayne; Trevor W Robbins; Roger A Barker Journal: J Neurol Neurosurg Psychiatry Date: 2013-06-18 Impact factor: 10.154
Authors: Reut Avinun; Adam Nevo; Spenser R Radtke; Bartholomew D Brigidi; Ahmad R Hariri Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-07-09 Impact factor: 5.270
Authors: Cristoforo Comi; Marco Ferrari; Franca Marino; Luca Magistrelli; Roberto Cantello; Giulio Riboldazzi; Maria Laura Ester Bianchi; Giorgio Bono; Marco Cosentino Journal: Int J Mol Sci Date: 2017-01-24 Impact factor: 5.923
Authors: Liana Basova; Julia A Najera; Nikki Bortell; Di Wang; Rosita Moya; Alexander Lindsey; Svetlana Semenova; Ronald J Ellis; Maria Cecilia Garibaldi Marcondes Journal: PLoS One Date: 2018-06-26 Impact factor: 3.240
Authors: Yu Jiang; Baoying Liu; Chuancheng Wu; Xiaoyan Gao; Yaoqin Lu; Yulong Lian; Jiwen Liu Journal: Int J Environ Res Public Health Date: 2020-11-05 Impact factor: 3.390